Boehringer Ingelheim, NIPER Hajipur MoU
Analysis based on 8 articles · First reported Apr 23, 2026 · Last updated Apr 27, 2026
The collaboration between Boehringer Ingelheim and NIPER Hajipur is expected to foster innovation in India's pharmaceutical sector, potentially leading to new drug discoveries and improved healthcare access. This aligns with the Government of India's Biopharma SHAKTI initiative, signaling a positive outlook for the industry's growth and talent development.
Boehringer Ingelheim India Private Limited and the National Institute of Pharmaceutical Education and Research (NIPER), Hajipur, signed a five-year Memorandum of Understanding (MoU) to advance pharmaceutical research, education, and innovation. This partnership will provide NIPER Hajipur researchers and students with access to Boehringer Ingelheim's global open science platform, opnMe®, which offers well-characterized pre-clinical tool compounds free of charge. The collaboration aims to strengthen India's talent pipeline for pharmaceutical innovation, particularly in Bihar and eastern India. The MoU aligns with the Government of India's Viksit Bharat vision and the Biopharma SHAKTI initiative, a national mission to accelerate India's transition to innovation-led biopharmaceutical excellence. Key figures present at the signing included Manoj Joshi, Secretary of the India — Ministry of Chemicals and Fertilizers, Prof. K. Ruckmani, Director of NIPER Hajipur, and Meenal Gauri, Managing Director of Boehringer Ingelheim India. The initiative is expected to bridge the gap between academic research and industry expertise, contributing to the development of future-ready scientific talent and more effective therapies for Indian patients.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard